SCHEMBL1100192

SCHEMBL1100192

COC(=O)c1ccc(S(=O)(=O)Nc2sc3ccccc3c2C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CMA1 P23946 2/20 0.53
ALDH1A1 P00352 5/20 0.46
KMT2A Q03164 4/20 0.46
MAPT P10636 3/20 0.46
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
TSHR P16473 2/20 0.46
GAA P10253 2/20 0.46
ALOX15 P16050 2/20 0.46
CYP2C9 P11712 3/20 0.45
TCF4 P15884 1/20 0.45
CTNNB1 P35222 1/20 0.45
FBP1 P09467 1/20 0.45
PLAU P00749 1/20 0.45
ACLY P53396 1/20 0.45
KDM4E B2RXH2 3/20 0.44
MEN1 O00255 3/20 0.44
LMNA P02545 2/20 0.44
HPGD P15428 2/20 0.44
CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1098803 0.88 ACLY (0.52) CMA1ALDH1A1KMT2AACLYMEN1
SCHEMBL1098725 0.86 ACLY (0.51) CMA1ALDH1A1KMT2AMAPTHTT
SCHEMBL1101435 0.85 PLAU (0.45) CMA1ALDH1A1KMT2AMAPTHTT
SCHEMBL10299805 0.83 KEAP1 (0.56) ALDH1A1KMT2AMAPTHTTSMN1; SMN2
SCHEMBL1099795 0.83 KDM4E (0.45) CMA1ALDH1A1KMT2AMAPTHTT
SCHEMBL1107226 0.82 CMA1 (0.56) CMA1ALDH1A1KMT2AMAPTGAA
SCHEMBL11888065 0.79 ACLY (0.42) CYP2C9ACLYCYP2C19
SCHEMBL1107222 0.74 PLAU (0.54) ALDH1A1KMT2AMAPTHTTSMN1; SMN2
SCHEMBL1098804 0.74 TRPM8 (0.57) CMA1ALDH1A1KMT2AMAPTFBP1
SCHEMBL2061430 0.73 HSD11B1 (0.45) CMA1ALDH1A1KMT2AMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8216547-B2 Radiolabelled TRP M8 receptor ligands JANSSEN PHARMACEUTICA NV (BE) 2012-07-10 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20100015053-A1 RADIOLABELLED TRP M8 RECEPTOR LIGANDS JANSSEN PHARMACEUTICA NV (BE) 2010-01-21 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed
WO-2009012430-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100015053-A1 RADIOLABELLED TRP M8 RECEPTOR LIGANDS TRPM8, TRPM7, GPR68 CMA1 1063/4885ALDH1A1 4518/4885KMT2A 2810/4885
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 CMA1 2577/4885ALDH1A1 3091/4885KMT2A 1231/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 CMA1 2577/4885ALDH1A1 3091/4885KMT2A 1231/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 CMA1 2577/4885ALDH1A1 3091/4885KMT2A 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.